The company operates as a holding company, currently investing in a pharmacy business that sells pharmaceuticals, cosmetics, dietary supplements, medical equipment, and various health products. It also engages in research and development with external research teams and outsources manufacturing to distribute health products and innovations.
| 9M25 | 9M24 | 2024 | 2023 |
|---|
| Revenues | 1,692.60 | 1,478.97 | 2,017.89 | 1,659.31 |
| Expenses | 1,620.78 | 1,415.69 | 1,916.05 | 1,558.59 |
| Net Profit (Loss) | 50.03 | 47.07 | 78.26 | 74.68 |
| Assets | 1,500.46 | 1,497.23 | 1,499.06 | 1,382.35 |
| Liabilities | 527.40 | 522.91 | 493.23 | 414.29 |
| Shareholders' Equity | 973.06 | 974.32 | 1,005.82 | 968.05 |
| Operating | 125.18 | 62.60 | 88.76 | 91.26 |
| Investing | -112.98 | -164.15 | -171.89 | 177.28 |
| Financing | -121.94 | -70.93 | -83.01 | -80.08 |
| EPS (Baht) | 0.19 | 0.17 | 0.29 | 0.27 |
| GP Margin (%) | 23.67 | 22.72 | 23.51 | 23.06 |
| NP Margin (%) | 2.96 | 3.18 | 3.88 | 4.50 |
| D/E Ratio (x) | 0.54 | 0.54 | 0.49 | 0.43 |
| ROE (%) | 8.34 | 8.03 | 7.93 | 7.82 |
| ROA (%) | 7.36 | 7.26 | 7.08 | 7.50 |
The company group has continuous branch expansion plans, focusing on the Bangkok metropolitan area and surrounding provinces due to their high market value. There is a plan to open 9 branches in 2025. In addition, the company group plans to add new innovative product items under its own brand and expand distribution channels outside the company network.
- Promotes environmental sustainability by cutting plastic and cardboard waste, digitizing workflows via ERP, and piloting e-Tax systems with partners as of 2024.
- In 2024, our pharmacies serve as collection points for the "Pharmaceutical Blister Pack Recycling Program," repurposing foil waste into sustainable value.
- Launched an employee waste-sorting campaign to reduce global warming and track progress per the 2025 SET policy.
- Recognizes the importance of strong communities and sustainable social development by participating in and promoting various activities in public health, education, and Buddhism.
- Collaborates with iRedcross on the "Parkinson's Support Project" to support the identification and care of Parkinson's patients, helping them receive appropriate care and improve their quality of life.
- Organized the 2025 seminar "Raising Healthy and Safe Children," in collaboration with Singapore International Schools, to strengthen parental knowledge, reduce the spread of disease in schools, and sustainably enhance the health of Thai families.
- Supported the “Healthy City @ Krungthonburi (3rd Edition)” event in Bang Khun Thian and Chom Thong districts, in collaboration with the Bangkok Metropolitan Administration, Bang Khun Thian Geriatric Hospital, Taksin Hospital, the Bang Khun Thian District Office, and the Chom Thong District Office, on 28 September 2025.
Invests in pharmaceutical retail and research and development businesses in collaboration with external research teams to distribute innovative health products. Owns four pharmacy brands with 69 branches in Bangkok and surrounding areas, and three innovative product brands: "Prime" for dietary supplements, "Besuto" for health and hygiene products, and "Q" health products from herbal innovations.
In 9M2025, the Group’s total sales revenue reached 1,663.73 million baht, representing a 14.70% increase YOY. Retail sales remained the primary revenue driver, accounting for 99.11% of the total.
All product segments posted YOY growth, Personal Healthcare products led with a 25.46% increase, followed by Medicine & Dietary Supplement products at 14.26%.
Other revenue rose 36.97% YOY, driven by the expansion of branches and sales areas, resulting in increased service income, as well as continued growth in Personal Healthcare sales that further supported service income from this segment.
- As of September 30, 2025, the Group operated 69 pharmacy branches. During 9M2025, the Group opened 6 new branches and closed 1 branch "Vitamin Club" at Central Pinklao in Q2 2025.
- In Q2 2025, the Group launched innovative herbal products under the "Q" brand which are Herbal Mouth Spray Q Brand and Herbal Nasal Spray Q Brand. These products reduce viral accumulation and are tested for inhibitory effectiveness against Influenza A (H1N1) and RSV. Additionally, the Probio 14 Plus supplement was launched under the "Prime" brand.
- In Q3 2025, 5 new SKUs were launched under the "Q" brand, including Brightening Essence, Anti-Hair Loss Intensive Shampoo for Women, Anti-Hair Loss Intensive Serum, Facial Gentle Foam, and Daily Moisture Body Lotion.
- Since founding the drugstore 30 years ago, the Group has sourced from two major distributors. The partnership has gone well. However, the Group has regularly reviewed new suppliers to ensure it secures sufficient products.
- In terms of competition risk, the Group focuses on expanding branches to strategic locations in Bangkok and having pharmacists stationed at all branches to guarantee superior quality of services.
- The Group is widely recognized in pharmacist professional group, as it has been offering internship programs for pharmaceutical students from leading universities for years. This has efficiently mitigated the risk of pharmacist shortage.
- Silver Medal, Innovation: Cell Matrix Technology - Prime VISION INVENTION GENEVA EVALUATION DAYS; March 28, 2022
- Gold Medal Award, Innovation: Prime MOVX2 - 2022 Japan Design, Idea & Invention Expo; July 1-3, 2022
- Gold Medal Award, Innovation: Prime KIN - 2024 Japan Design, Idea & Invention Expo; July 5-7, 2024
- Gold Medal Award, Innovation and Invention: Prime Bioenhancz - 2024 PRIX EIFFEL, Idea & Invention Expo; November 12, 2024
- Special Award, Innovation: Prime Bioenhancz - Innovation Initiative Co-operative Inc. (CANADA); November 12-13, 2024
- Silver Medal Award, Innovation and Invention: Q Herbal Mouth Spray - 2024 PRIX EIFFEL, Idea & Invention Expo; November 12-13, 2024
| as of 30/09/25 | HL | SERVICE | mai |
|---|---|---|---|
| P/E (X) | 23.76 | 51.02 | 72.21 |
| P/BV (X) | 2.09 | 1.72 | 1.27 |
| Dividend yield (%) | 2.28 | 3.07 | 3.64 |
| 30/09/25 | 30/12/24 | 28/12/23 | |
|---|---|---|---|
| Market Cap (MB) | 2,067.20 | 2,774.40 | 2,828.80 |
| Price (B/Share) | 7.60 | 10.20 | 10.40 |
| P/E (X) | 23.76 | 36.14 | 35.81 |
| P/BV (X) | 2.09 | 2.85 | 3.02 |